The ARQL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARQL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARQL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARQL Detailed Price Forecast - CNN Money||View ARQL Detailed Summary - Google Finance|
|View ARQL Detailed Summary - Yahoo! Finance||View ARQL Stock Research & Analysis - Zacks.com|
|View ARQL Trends & Analysis - Trade-Ideas||View ARQL Major Holders - Barrons|
|View ARQL Call Transcripts - NASDAQ||View ARQL Breaking News & Analysis - Seeking Alpha|
|View ARQL Annual Report - CompanySpotlight.com||View ARQL OTC Short Report - OTCShortReport.com|
|View ARQL Fundamentals - TradeKing||View ARQL SEC Filings - Bar Chart|
|View Historical Prices for ARQL - The WSJ||View Performance/Total Return for ARQL - Morningstar|
|View the Analyst Estimates for ARQL - MarketWatch||View the Earnings History for ARQL - CNBC|
|View the ARQL Earnings - StockMarketWatch||View ARQL Buy or Sell Recommendations - MacroAxis|
|View the ARQL Bullish Patterns - American Bulls||View ARQL Short Pain Metrics - ShortPainBot.com|
|View ARQL Stock Mentions - StockTwits||View ARQL Stock Mentions - PennyStockTweets|
|View ARQL Stock Mentions - Twitter||View ARQL Investment Forum News - Investor Hub|
|View ARQL Stock Mentions - Yahoo! Message Board||View ARQL Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARQL - SECform4.com||View Insider Transactions for ARQL - Insider Cow|
|View ARQL Major Holdings Summary - CNBC||View Insider Disclosure for ARQL - OTC Markets|
|View Insider Transactions for ARQL - Yahoo! Finance||View Institutional Holdings for ARQL - NASDAQ|
|View ARQL Stock Insight & Charts - FinViz.com||View ARQL Investment Charts - StockCharts.com|
|View ARQL Stock Overview & Charts - BarChart||View ARQL User Generated Charts - Trading View|
ArQule, Inc. (ARQL): Are Hedge Funds Right About This Stock?
Posted on Tuesday December 11, 2018
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
Posted on Monday December 03, 2018
ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego.
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Posted on Sunday December 02, 2018
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
Posted on Thursday November 29, 2018
ArQule, Inc. (ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies (ARQ 531-101) that are being presented in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition on December 3, 2018 in San Diego. The C481S-mutation is a known resistance mechanism for first generation irreversible BTK inhibitors.